Current Report Filing (8-k)
08 Mai 2023 - 11:22PM
Edgar (US Regulatory)
0000879169 false 0000879169 2023-05-04
2023-05-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 4, 2023
INCYTE CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or Other Jurisdiction of
Incorporation) |
|
001-12400
(Commission File Number) |
|
94-3136539
(I.R.S. Employer
Identification No.) |
1801 Augustine Cut-Off |
|
|
Wilmington,
DE |
|
19803 |
(Address of principal
executive offices) |
|
(Zip Code) |
(302)
498-6700
(Registrant’s telephone number,
including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligations of the
registrant under any of the following provisions (see General
Instruction A.2. below):
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240-13e-4(c)) |
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class |
|
Trading Symbol |
|
Name of exchange on which registered |
Common Stock, $.001 par value per share |
|
INCY |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b–2 of the Securities
Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging
growth company ¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ¨
|
Item 8.01 |
Item 8.01 Other Events |
Effective May 4, 2023, the Board of Directors of Incyte Corporation
(the “Company”) approved the appointment of Pablo J. Cagnoni, M.D.,
as President, Research and Development, of the Company, with such
appointment to be effective June 5, 2023.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
Dated: May 8, 2023
|
INCYTE CORPORATION |
|
|
|
By: |
/s/ Maria E. Pasquale |
|
|
Maria E. Pasquale |
|
|
Executive Vice President and |
|
|
General Counsel |
Incyte (NASDAQ:INCY)
Historical Stock Chart
Von Sep 2023 bis Okt 2023
Incyte (NASDAQ:INCY)
Historical Stock Chart
Von Okt 2022 bis Okt 2023